ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 133

Cross-Sectional Neurocognitive Data Do Not Support a Transition From Fibrofog To Alzheimer’s Disease In Fibromyalgia Patients

Robert S. Katz1 and Frank Leavitt2, 1Rush Medical College, Chicago, IL, 2Rush University Medical Center, Chicago, IL

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: fibromyalgia

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders and Pain I

Session Type: Abstract Submissions (ACR)

Background/Purpose: The issue of progressive decline in cognitive abilities is a source of concern to many patients with fibromyalgia.  The fear of progressing from fibrofog in middle age  to Alzheimer’s or other forms of dementia is central to the worries shared by many.  To determine if cognitive impairment progresses over time in fibromyalgia, a cross sectional study of cognitive functioning was conducted with a battery of neuro-cognitive tests known to be sensitive to cognitive change. 

Methods: In a cross-sectional study, cognitive disparities on 14 neurocognitive measures were evaluated in two cohorts of fibromyalgia subjects who met the new criteria for fibromyalgia.   The first cohort contained 69 subjects with a short duration of cognitive problems (12 months or less).  The second cohort contained 39 subjects with a long duration of cognitive problems (≥ 84 months or greater). 

Results: The two groups were similar in terms of mean (±SE) education (15.0±2.2 vs. 14.9±2.5), Vocabulary Scale score (11.2 ± 2.3 vs. 11.9 ± 2.8), and depression  (17.5±9.4 vs. 17.8±9.3).   The Long Duration Cohort was significantly older (45.6 ± 10.8 vs. 52.3± 9.1 years; p<0.001).  Cognitive data of the two cohorts are displayed in Table 1.  No significant differences were found between the two duration derived cohorts on 13 of the 14 cognitive measures.  Performance declined with the duration of cognitive problems on Trails A, a measure of spatial scanning and cognitive sequencing.  However, the skills of Trails A are incorporated inTrails B, where performance of the two groups was essentially equivalent.  Measures of episodic memory and processing speed, markers of preclinical Alzheimer’s disease, are in the normal range for both cohorts

Conclusion: Fibromyalgia patients’ fear of developing Alzheimer’s or other forms of dementia was not borne out by the data. Duration of cognitive problems was not a determiner of cognitive severity. People with a duration of 84 months or greater were not significantly more cognitively disabled than those with a duration of 12 months or less. The data do not support later transitions to dementia.  The fact that individuals suffering cognitive dysfunction from 7 to 26 years did not exhibit a broad based deficit relative to those suffering cognitive dysfunction for a duration of a year of less should allay the worries of many with fibromyalgia who fear that fibrofog in the middle years is the start of a dementing process. .


Disclosure:

R. S. Katz,
None;

F. Leavitt,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cross-sectional-neurocognitive-data-do-not-support-a-transition-from-fibrofog-to-alzheimers-disease-in-fibromyalgia-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology